发明授权
![Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors](/docs/US/2017-01-17/US09546173B2/abs.jpg.600x600.jpg)
- 专利标题： Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors
- 专利标题（中）： 取代的吡咯并[3,4-d]嘧啶作为激酶抑制剂
-
申请号： US14428546申请日： 2013-09-17
-
公开(公告)号： US09546173B2公开(公告)日： 2017-01-17
- 发明人: Michael Patrick Dillon , Mika Lindvall , Daniel Poon , Savithri Ramurthy , Vivek Rauniyar , Cynthia Shafer , Sharadha Subramanian , Huw Rowland Tanner
- 申请人： Michael Patrick Dillon , Mika Lindvall , Daniel Poon , Savithri Ramurthy , Vivek Rauniyar , Cynthia Shafer , Sharadha Subramanian , Huw Rowland Tanner
- 申请人地址： CH Basel
- 专利权人： Novartis AG
- 当前专利权人： Novartis AG
- 当前专利权人地址： CH Basel
- 代理商 Shawn D. Britt
- 国际申请： PCT/US2013/060032 WO 20130917
- 国际公布： WO2014/047020 WO 20140327
- 主分类号： A61K31/519
- IPC分类号： A61K31/519 ; C07D239/70 ; C07D487/04 ; C07D207/36 ; A61K31/527 ; A61K45/06 ; C07D487/10
![Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors](/abs-image/US/2017/01/17/US09546173B2/abs.jpg.150x150.jpg)
摘要：
The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics.
公开/授权文献
- US20150274733A1 DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS 公开/授权日：2015-10-01
信息查询
IPC分类:
